143 related articles for article (PubMed ID: 36198460)
21. Cost-effectiveness of rotavirus vaccination in Kenya and Uganda.
Sigei C; Odaga J; Mvundura M; Madrid Y; Clark AD; ;
Vaccine; 2015 May; 33 Suppl 1():A109-18. PubMed ID: 25919149
[TBL] [Abstract][Full Text] [Related]
22. Economic evaluation of the introduction of rotavirus vaccine in Hong Kong.
Yeung KHT; Lin SL; Clark A; McGhee SM; Janusz CB; Atherly D; Chan KC; Nelson EAS
Vaccine; 2021 Jan; 39(1):45-58. PubMed ID: 33221066
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of rotavirus vaccination in Albania.
Ahmeti A; Preza I; Simaku A; Nelaj E; Clark AD; Felix Garcia AG; Lara C; Hoestlandt C; Blau J; Bino S
Vaccine; 2015 May; 33 Suppl 1():A201-8. PubMed ID: 25919162
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of childhood rotavirus vaccination in Taiwan.
Wu CL; Yang YC; Huang LM; Chen KT
Vaccine; 2009 Mar; 27(10):1492-9. PubMed ID: 19186200
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of a new rotavirus vaccination program in Pakistan: a decision tree model.
Patel HD; Roberts ET; Constenla DO
Vaccine; 2013 Dec; 31(51):6072-8. PubMed ID: 24176497
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of childhood rotavirus vaccination in Germany.
Aidelsburger P; Grabein K; Böhm K; Dietl M; Wasem J; Koch J; Ultsch B; Weidemann F; Wichmann O
Vaccine; 2014 Apr; 32(17):1964-74. PubMed ID: 24561052
[TBL] [Abstract][Full Text] [Related]
27. Association of Rotavirus Vaccines With Reduction in Rotavirus Gastroenteritis in Children Younger Than 5 Years: A Systematic Review and Meta-analysis of Randomized Clinical Trials and Observational Studies.
Sun ZW; Fu Y; Lu HL; Yang RX; Goyal H; Jiang Y; Xu HG
JAMA Pediatr; 2021 Jul; 175(7):e210347. PubMed ID: 33970192
[TBL] [Abstract][Full Text] [Related]
28. Introducing Rotavirus Vaccination in Nigeria: Economic Evaluation and Implications.
Okafor CE
Pharmacoecon Open; 2021 Sep; 5(3):545-557. PubMed ID: 33410094
[TBL] [Abstract][Full Text] [Related]
29. A cost effectiveness and capacity analysis for the introduction of universal rotavirus vaccination in Kenya: comparison between Rotarix and RotaTeq vaccines.
van Hoek AJ; Ngama M; Ismail A; Chuma J; Cheburet S; Mutonga D; Kamau T; Nokes DJ
PLoS One; 2012; 7(10):e47511. PubMed ID: 23115650
[TBL] [Abstract][Full Text] [Related]
30. Does the Choice of Health Metric, DALY or QALY, Influence Conclusions of Health Economic Evaluation? A Case Study of Rotavirus Vaccine in Burundi.
Niyibitegeka F; Thavorncharoensap M; Riewpaiboon A; Youngkong S
Appl Health Econ Health Policy; 2022 Sep; 20(5):707-716. PubMed ID: 35469393
[TBL] [Abstract][Full Text] [Related]
31. Effect of rotavirus genetic diversity on vaccine impact.
Sadiq A; Bostan N; Jadoon Khan ; Aziz A
Rev Med Virol; 2022 Jan; 32(1):e2259. PubMed ID: 34997676
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France.
Standaert B; Parez N; Tehard B; Colin X; Detournay B
Appl Health Econ Health Policy; 2008; 6(4):199-216. PubMed ID: 19382820
[TBL] [Abstract][Full Text] [Related]
33. Evaluating the potential risks and benefits of infant rotavirus vaccination in England.
Clark A; Jit M; Andrews N; Atchison C; Edmunds WJ; Sanderson C
Vaccine; 2014 Jun; 32(29):3604-10. PubMed ID: 24814524
[TBL] [Abstract][Full Text] [Related]
34. The cost-effectiveness of rotavirus vaccination in Malawi.
Berry SA; Johns B; Shih C; Berry AA; Walker DG
J Infect Dis; 2010 Sep; 202 Suppl(Suppl 1):S108-15. PubMed ID: 20684689
[TBL] [Abstract][Full Text] [Related]
35. Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination.
Jit M; Edmunds WJ
Vaccine; 2007 May; 25(20):3971-9. PubMed ID: 17400341
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of rotavirus vaccination: exploring caregiver(s) and "no medical care'' disease impact in Belgium.
Bilcke J; Van Damme P; Beutels P
Med Decis Making; 2009; 29(1):33-50. PubMed ID: 18948433
[TBL] [Abstract][Full Text] [Related]
37. Established and new rotavirus vaccines: a comprehensive review for healthcare professionals.
Vetter V; Gardner RC; Debrus S; Benninghoff B; Pereira P
Hum Vaccin Immunother; 2022 Dec; 18(1):1870395. PubMed ID: 33605839
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness analysis of the implementation of a National Immunization Program for rotavirus vaccination in a country with a low rotavirus gastroenteritis-related mortality: A South Korean study.
Lee H; Park SY; Clark A; Debellut F; Pecenka C; Kim DS; Kim HM; Kim JH; Cho H; Kim AY; Lee M; Jung SY; Seong BL; Kang HY
Vaccine; 2019 Aug; 37(35):4987-4995. PubMed ID: 31326252
[TBL] [Abstract][Full Text] [Related]
39. Global Experience With Rotavirus Vaccines.
Burke RM; Tate JE; Parashar UD
J Infect Dis; 2021 Dec; 224(12 Suppl 2):S792-S800. PubMed ID: 34374426
[TBL] [Abstract][Full Text] [Related]
40. Estimating the economic impact of pneumococcal conjugate, Haemophilus influenzae type b and rotavirus vaccines in India: National and state-level analyses.
Constenla D; Liu T
Vaccine; 2019 Dec; 37(52):7547-7559. PubMed ID: 31607600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
